The idea is that SYH2086 can be paired with Rezdiffra, a selective thyroid hormone receptor agonist that became the first FDA-approved drug for metabolic dysfunction-associated steatohepatitis (MASH) ...

Madrigal Pharmaceuticals (NASDAQ:MDGL) said it has signed a global licensing deal with CSPC Pharmaceutical for SYH2086, a new ...

West Conshohocken’s Madrigal Pharmaceuticals earned a major win with the FDA approval of its first commercial product, reports John George for the Philadelphia ...

Madrigal will study SYH2086 in combination with Rezdiffra for metabolic dysfunction-associated steatohepatitis, aiming for ...

Strong Q1 sales of $137.3M showcase Madrigal Pharmaceuticals, Inc.'s Rezdiffra's growth in non-cirrhotic NASH. Click for my ...

Hong Kong-based CSPC will receive $120 million from Madrigal under the deal. Elsewhere, Apellis and PTC Therapeutics won FDA ...

CEO touts 'amazing' sales success of new drug, but firm's stock slumps Montco firm's shares soar on huge sales increase of ...

Madrigal Pharmaceuticals (NASDAQ:MDGL) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July ...

U.S. drugmaker Madrigal Pharmaceuticals has struck a licensing deal with CSPC Pharmaceutical Group that could be worth more than $2 billion for the Chinese company if it results in a new drug for a ...

USA-based Madrigal Pharmaceuticals today announced that it has entered into an exclusive global license agreement with CSPC ...

Madrigal Pharmaceuticals secures global rights to SYH2086, aiming to enhance MASH treatment with innovative combination ...